Труды авторов, использованные при подготовке статей по раку молочной железы на сайте Доммедика

В ходе подготовки статей по раку молочной железы для пользователей сайта ДомМедика использованы труды признанных иностранных авторов представленных ниже.

В статьях использованы следующие сокращения:

  • АДФ — аденозиндифосфат
  • АИХ — аменорея, индуцированная химиотерапией
  • ГнРГ — гонадотропин-рилизинг гормон
  • ГР — гомологичная рекомбинация
  • ДИ — доверительный интервал
  • ДНК — дезоксирибонуклеиновая кислота
  • ИА — ингибиторы ароматазы
  • ИМТ — индекс массы тела
  • иРМЖ — ипсилатеральный рак молочной железы кРМЖ — контралатеральный рак молочной железы
  • КСЯ — контролируемая стимуляция яичников мРНК — матричная рибонуклеиновая кислота МРР — местно-регионарный рецидив
  • МРТ — магнитно-резонансная томография
  • ОР — относительный риск
  • ОСО — органосохраняющая операция
  • ПК — протоковая карцинома
  • ПМЛТ — постмастэктомическая лучевая терапия
  • ПНЯ — преждевременная недостаточность яичников пПО — полный патоморфологический ответ
  • ПФЯ — подавление функций яичников РМЖ — рак молочной железы
  • РНК — рибонуклеиновая кислота
  • тнРМЖ — тройной негативный рак молочной железы
  • УЗИ — ультразвуковое исследование ЭТ — эндокринная терапия
  • ADM (от англ, acellular dermal matrix) — бесклеточная кожная матрица
  • DRFI (от англ, distant recurrence-free interval) — выживаемость без отдаленных рецидивов
  • EORTC (от англ. European Organization for Research and Treatment of Cancer) — Европейская организация по исследованию и лечению рака
  • ER (от англ, estrogen receptor) — рецептор эстрогена
  • ESMO (от англ. European Society for Medical Oncology) — Европейское общество медицинской онкологии
  • HER (от англ, human epidermal growth factor receptor) — рецептор эпидермального фактора роста
  • IBCSG (от англ. International Breast Cancer Study Group) - Международная группа по изучению рака молочной железы
  • LD (от лат. latissimus dorsi) — широчайшая мышца спины
  • NCCN (от англ. National Comprehensive Cancer Network) — Национальная комплексная онкологическая сеть
  • РАМ50 (от англ, prediction analysis of the microarrays) — количественный анализ 50 генов с помощью полимеразной цепной реакции в режиме реального времени
  • PARP (от англ. poly-(ADP-ribose) polymerases) — поли-(АДФ-рибоза)-полимераза
  • PgR (от англ, progesterone receptor) — рецептор прогестерона
  • PI3K (от англ, phosphoinositide 3-kinase) — фосфоинозитид-3-киназа
  • ROR-PT (от англ, risk of recurrence score) — балл риска рецидива
  • SEER (от англ. Surveillance, Epidemiology, and End Results) — анализ течения, распространенности и исходов злокачественных новообразований

Авторы трудов, которые использованы для подготовки статей:

  1. Laurberg Т, Alsner J., Tramm Т, Jensen V., Lyngholm C.D., Christiansen P.M. et al. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients // Acta Oncol. 2017. Vol. 56, N 1. P. 59-67.
  2. de Bock G.H., van der Hage J.A., Putter H., Bonnema J., Bartelink H., van de Velde C.J. Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies // Eur. J. Cancer. 2006. Vol. 42, N 3. P. 351-356.
  3. Kim S.W., Chun M., Han S„ Jung Y.S., Choi J.H., Kang S.Y. et al. Young age is associated with increased locoregional recurrence in node-positive breast cancer with luminal subtypes // Cancer Res. Treat. 2017. Vol. 49, N 2. P. 484-493.
  4. Braunstein L.Z., Taghian A.G., Niemierko A., Salama L., Capuco A., Bellon J.R. et al. Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy // Breast Cancer Res. Treat. 2017. Vol. 161, N 1. P. 173-179.
  5. Arvold N.D., Taghian A.G., Niemierko A., Abi Raad R.F., Sreedhara M., Nguyen P.L. et al. Age, breast cancer subtype approximation, and local recurrence after breastconserving therapy //J. Clin. Oncol. 2011. Vol. 29, N 29. P. 3885-3891.
  6. Harrold E.V, Turner B.C., Matloff E.T, Pathare P, Beinfield M., McKhann C. et al. Local recurrence in the conservatively treated breast cancer patient: a correlation with age and family history // Cancer J. Sci. Am. 1998. Vol. 4, N 5. P. 302-307.
  7. van der Leest М., Evers L., van der Sangen M.J., Poortmans P.M., van de Poll-Franse L.V., Vulto AJ. et al. The safety of breast-conserving therapy in patients with breast cancer aged < or = 40 years // Cancer. 2007. Vol. 109, N 10. P. 1957-1964.
  8. van Laar C., van der Sangen MJ., Poortmans P.M., Nieuwenhuijzen G.A., Roukema J.A., Roumen R.M. et al. Local recurrence following breast-conserving treatment in women aged 40 years or younger: trends in risk and the impact on prognosis in a population- based cohort of 1143 patients // Eur. J. Cancer. 2013. Vol. 49, N 15. P. 3093-3101.
  9. Bartelink H., Maingon P, Poortmans P, Weltens C., Fourquet A., Jager J. et al.; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial // Lancet Oncol. 2015. Vol. 16, N 1. P. 47-56.
  10. Vrieling C., Collette L., Fourquet A., Hoogenraad W.J., Horiot J.C., Jager JJ. et al.; EORTC Radiotherapy, Breast Cancer Groups. Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? // Eur. J. Cancer. 2003. Vol. 39, N 7. P. 932-944.
  11. Radosa J.C., Eaton A., Stempel M., Khander A., Liedtke C., Solomayer E.E et al. Evaluation of local and distant recurrence patterns in patients with triple-negative breast cancer according to age // Ann. Surg. Oncol. 2017. Vol. 24, N 3. P. 698-704.
  12. Kent C., Elorton J., Blitzblau R., Koontz B.F. Whose disease will recur after mastectomy for early stage, node-negative breast cancer? A systematic review // Clin. Breast Cancer. 2015. Vol. 15, N 6. P. 403-412.
  13. Karlsson P, Cole B.F., Chua B.H., Price K.N., Lindtner J., Collins J.P et al.; International Breast Cancer Study Group. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report // Ann. Oncol. 2012. Vol. 23, N 11. P. 2852-2858.
  14. van der Sangen M.J., van de Wiel F.M., Poortmans P.M., Tjan-Heijnen V.C., Nieuwenhuijzen G.A., Roumen R.M. et al. Are breast conservation and mastectomy equally effective in the treatment of young women with early breast cancer? Longterm results of a population-based cohort of 1,451 patients aged <40 years // Breast Cancer Res. Treat. 2011. Vol. 127, N 1. P. 207-215.
  15. Bantema-Joppe E.J., van den Heuvel E.R., de Munck L., de Bock G.H., Smit W.G., Timmer PR. et al. Impact of primary local treatment on the development of distant metastases or death through locoregional recurrence in young breast cancer patients // Breast Cancer Res. Treat. 2013. Vol. 140, N 3. P. 577-585.
  16. Vila J., Gandini S., Gentilini O. Overall survival according to type of surgery in young (<40 years) early breast cancer patients: a systematic meta-analysis comparing breast-conserving surgery versus mastectomy // Breast. 2015. Vol. 24, N3. P. 175-181.
  17. Ye J.C., Yan W, Christos PJ., Nori D., Ravi A. Equivalent survival with mastectomy or breast-conserving surgery plus radiation in young women aged <40 years with early-stage breast cancer: a national registry-based stage-by-stage comparison // Clin. Breast Cancer. 2015. Vol. 15, N 5. P. 390-397.
  18. Bantema-Joppe E.J., de Munck L., Visser O., Willemse P.H., Langendijk J.A., Siesling S. et al. Early-stage young breast cancer patients: impact of local treatment on survival // Int. J. Radiat. Oncol. Biol. Phys. 2011. Vol. 81, N 4. P. e553-e559.
  19. Kim H.J., Han W., Yi O.V., Shin H.C., Ahn S.K., Koh B.S. et al. Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype // Breast Cancer Res. Treat. 2011. Vol. 130, N 2. P. 499-505.
  20. van der Sangen M.J., Poortmans P.M., Scheepers S.W., Lemaire B.M., van Berio C.L., Tjan-Heijnen VC. et al. Prognosis following local recurrence after breast conserving treatment in young women with early breast cancer // Eur. J. Surg. Oncol. 2013. Vol. 39, N 8. P. 892-898.
  21. Courdi A., Doyen J., Gal J., Chamorey E. Local recurrence after breast cancer affects specific survival differently according to patient age // Oncology. 2010. Vol. 79, N 5-6. P. 349-354.
  22. Miles R.C., Gullerud R.E., Lohse C.M., Jakub J.W., Degnim A.C., Boughey J.C. Local recurrence after breast-conserving surgery: multivariable analysis of risk factors and the impact of young age // Ann. Surg. Oncol. 2012. Vol. 19, N 4. P. 1153-1159.
  23. Guinot J.L., Baixauli-Perez C., Soler P, Tortajada M.I., Moreno A., Santos M.A. et al. High-dose-rate brachytherapy boost effect on local tumor control in young women with breast cancer // Int. J. Radiat. Oncol. Biol. Phys. 2015. Vol. 91, N 1. P. 165-171.
  24. Senkus E., Kyriakides S„ Ohno S., Penault-Llorca E, Poortmans P, Rutgers E. et al.; ESMO Guidelines Committee. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. 2015. Vol. 26, suppl. 5. P. v8-v30.
  25. URL: www.nccn.org/professionals/physician_gls/pdf/breast.pdf (date of access Nov 11, 2024)
  26. URL: clinicaltrials.gov/ct2/show/NCT00212121. (date of access Nov 11, 2024)
  27. Smith B.D., Bellon J.R., Blitzblau R., Freedman G., Haffty B., Hahn C. et al. Radiation therapy for the whole breast: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline // Pract. Radiat. Oncol. 2018. Vol. 8, N 3. P. 145-152.
  28. Polgar C., Van Limbergen E., Potter R., Kovacs G., Polo A., Lyczek J. et al.; GEC-ESTRO Breast Cancer Working Group. Patient selection for accelerated partialbreast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Europeen de Curietherapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) Breast Cancer Working Group based on clinical evidence (2009) // Radiother. Oncol. 2010. Vol. 94, N 3. P. 264-273.
  29. Correa C., Harris E.E., Leonardi M.C., Smith B.D., Taghian A.G., Thompson A.M. et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement // Pract. Radiat. Oncol. 2017. Vol. 7, N 2. P. 73-79.
  30. Shah C., Vicini E, Wazer D.E., Arthur D., Patel R.R. The American Brachytherapy Society consensus statement for accelerated partial breast irradiation // Brachytherapy. 2013. Vol. 12, N 4. P. 267-277.
  31. Sato К., Mizuno Y, Fuchikami Н., Kato М., Shimo Т, Kubota J. et al. Impact of young age on local control after partial breast irradiation in Japanese patients with early stage breast cancer // Breast Cancer. 2017. Vol. 24, N 1. P. 79-85.
  32. Wenz E, Sperk E., Budach W, Dunst J., Feyer P, Fietkau R. et al.; Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). DEGRO practical guidelines for radiotherapy of breast cancer IV: radiotherapy following mastectomy for invasive breast cancer // Strahlenther. Onkol. 2014. Vol. 190, N8. P. 705-714.
  33. Recht A., Comen E.A., Fine R.E., Fleming G.F., Hardenbergh PH., Ho A.Y. et al. Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update // J. Clin. Oncol. 2016. Vol. 34, N 36. P. 4431-4442.
  34. Curigliano G., Burstein H.J., Winer E.P., Gnant M., Dubsky P, Loibl S. Et al.; on behalf of the Panel Members of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017. De-escalating and escalating treatments for early stage breast cancer: the St Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 // Ann. Oncol. 2017. Vol. 28, N 8. P. 1700-1712.
  35. EBCTCG (Early Breast Cancer Trialists’ Collaborative Group); McGale P., Taylor C., Correa C., Cutter D., Duane E, Ewertz M. et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials // Lancet. 2014. Vol. 383, N 9935. P. 2127-2135.
  36. Quan M.L., Osman E, McCready D., Fernandes K., Sutradhar R., Paszat L. Postmastectomy radiation and recurrence patterns in breast cancer patients younger than age 35 years: a population-based cohort // Ann. Surg. Oncol. 2014. Vol. 21, N2. P. 395-400.
  37. Garg A.K., Oh J.L., Oswald M.J., Huang E., Strom E.A., Perkins G.H. et al. Effect of postmastectomy radiotherapy in patients <35 years old with stage II—III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy // Int. J. Radiat. Oncol. Biol. Phys. 2007. Vol. 69, N5. P. 1478-1483.
  38. Lammers E.J., Huibers P, van der Sangen MJ., van de Poll-Franse L.V., Poortmans P.M., Ernst M.F. et al. Factors contributing to improved local control after mastectomy in patients with breast cancer aged 40 years or younger // Breast. 2010. Vol. 19, N 1. P. 44-49.
  39. Yildirim E., Berberoglu U. Can a subgroup of node-negative breast carcinoma patients with Tl-2 tumor who may benefit from postmastectomy radiotherapy be identified? // Int. J. Radiat. Oncol. Biol. Phys. 2007. Vol. 68, N 4. P. 1024-1029.
  40. Abi-Raad R., Boutrus R., Wang R., Niemierko A., Macdonald S., Smith B. et al. Patterns and risk factors of locoregional recurrence in T1-T2 node negative breast cancer patients treated with mastectomy: implications for postmastectomy radiotherapy // Int. J. Radiat. Oncol. Biol. Phys. 2011. Vol. 81, N 3. P. el51-e157.
  41. Yan W, Christos P., Nori D., Chao K.S., Ravi A. Is there a cause-specific survival benefit of postmastectomy radiation therapy in women younger than age 50 with T3N0 invasive breast cancer? A SEER database analysis: outcomes by receptor status/race/age: analysis using the NCI Surveillance, Epidemiology, and End Results (SEER) database // Am. J. Clin. Oncol. 2013. Vol. 36, N 6. P. 552-557.
  42. Poortmans Р.М., Collette S., Kirkove C., Van Limbergen E., Budach V, Struikmans H. et al.; EORTC Radiation Oncology and Breast Cancer Groups. Internal mammary and medial supraclavicular irradiation in breast cancer // N. Engl. J. Med. 2015. Vol. 373, N 4. P. 317-327.
  43. Whelan T.J., Olivotto I.A., Parulekar W.R., Ackerman I., Chua B.H., Nabid A. et al.; MA.20 Study Investigators. Regional nodal irradiation in early-stage breast cancer // N. Engl. J. Med. 2015. Vol. 373, N 4. P. 307-316.
  44. Hennequin C., Bossard N., Servagi-Vernat S., Maingon P, Dubois J.B., Datchary J. et al. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy // Int. J. Radiat. Oncol. Biol. Phys. 2013. Vol. 86, N 5. P. 860-866.
  45. Thorsen L.B., Offersen B.V, Dano H., Berg M., Jensen I., Pedersen A.N. et al. DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer //J. Clin. Oncol. 2016. Vol. 34, N4. P 314-320.
  46. Kong I., Narod S.A., Taylor C., Paszat L., Saskin R., Nofech-Moses S. et al. Age at diagnosis predicts local recurrence in women treated with breastconserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis // Curr. Oncol. 2014. Vol. 21, N 1. P. e96-el04.
  47. Vicini F.A., Shaitelman S., Wilkinson J.B., Shah C., Ye H., Kestin L.L. et al. Longterm impact of young age at diagnosis on treatment outcome and patterns of failure in patients with ductal carcinoma in situ treated with breast-conserving therapy // Breast J. 2013. Vol. 19, N 4. P. 365-373.
  48. Omlin A., Amichetti M., Azria D., Cole B.F., Fourneret P, Poortmans P. et al. Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network // Lancet Oncol. 2006. Vol. 7, N 8. P. 652-656.
  49. Freedman R.A., Virgo K.S., Labadie J., He Y, Partridge A.H., Keating N.L. Receipt of locoregional therapy among young women with breast cancer // Breast Cancer Res. Treat. 2012. Vol. 135, N 3. P. 893-906.
  50. Pan I.W., Smith B.D., Shih Y.C. Factors contributing to underuse of radiation among younger women with breast cancer //J. Natl Cancer Inst. 2014. Vol. 106, N 1. Article ID djt340.
  51. Stovall M„ Smith S.A., Langholz B.M., Boice J.D. Jr, Shore R.E., Andersson M. et al.; Women’s Environmental, Cancer, and Radiation Epidemiology Study Collaborative Group. Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study // Int. J. Radiat. Oncol. Biol. Phys. 2008. Vol. 72, N 4. P. 1021-1030.
  52. Hooning M.J., Aleman В.М., Hauptmann М., Baaijens М.Н., Klijn J.G., Noyon R. et al. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer //J. Clin. Oncol. 2008. Vol. 26, N 34. P. 5561-5568.
  53. Darby S.C., McGale P., Taylor C.W., Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries // Lancet Oncol. 2005. Vol. 6, N 8. P. 557-565.

- Вернуться в оглавление раздела "Нейрофизиология"

Редактор: Искандер Милевски. Дата обновления публикации: 11.11.2023

    О сайте:

  1. Поиск по сайту
  2. Контакты и пользовательское соглашение

    О сайте:

  1. Контакты и пользовательское соглашение